IGF-1 deficiency: an important differential diagnosis in severe growth failure and its excellent response to rhIGF-1 replacement therapy

Dinesh Giri1, Martin O Savage2, Helen Storror2, Elaine Arnold2, Renuka Ramakrishnan1

1DEPARTMENT OF PAEDIATRIC ENDOCRINOLOGY, ALDER HEY CHILDREN’S HOSPITAL, LIVERPOOL, UK, 2BARTS AND THE LONDON SCHOOL OF MEDICINE AND DENTISTRY, WILLIAM HARVEY RESEARCH INSTITUTE, CENTRE FOR ENDOCRINOLOGY, QUEEN MARY UNIVERSITY OF LONDON

Background

Insulin-like growth factor-1 (IGF-1) is the key effector peptide in the control of normal growth. IGF-1 deficiency in the presence of normal growth hormone (GH) is associated with growth failure. This may be caused by primary defects in the GH-IGF-1 axis or by conditions such as malnutrition or chronic inflammation. Severe Primary IGF-1 deficiency (height <-3 SD, serum IGF-1 <2.5th centile, GH normal) is a licensed indication for rhIGF-1 therapy. We report a patient with severe failure to thrive, short stature and unexplained IGF-1 deficiency who showed an excellent response to rhIGF-1 therapy.

Case

- 10 month old girl with severe failure to thrive (weight: 4.2kg, -7.95 SDS, length 60.1cm, -4.40 SDS).
- Born at 36 weeks gestation weighing 2.85 kg.
- Non-consanguineous Caucasian parents
- No dysmorphism, No microcephaly
- No recurrent infections
- Good caloric intake.
- Gross motor delay
- Russell-Silver syndrome, skeletal dysplasia, malabsorption and chronic illness were excluded.

Investigations

<table>
<thead>
<tr>
<th>Glucagon stimulation</th>
<th>Peak GH 6.33 µg/l with a baseline of 1.51 µg/l.</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF1</td>
<td>Persistently undetectable(&lt;3.3nmol/l)</td>
</tr>
<tr>
<td>MRI Brain</td>
<td>Normal Pituitary</td>
</tr>
<tr>
<td>IGF-1 generation</td>
<td>IGF-1 undetectable(&lt;3.3nmol/l) after daily GH (35µg/kg/day x 4). IGFBP-3 increased from 0.5 to 1.3mg/l(NR 0.5-2.9)</td>
</tr>
<tr>
<td>GH receptor mutation</td>
<td>Negative</td>
</tr>
<tr>
<td>Thyroid Function test, ACTH, Cortisol</td>
<td>Normal</td>
</tr>
</tbody>
</table>

- GH therapy resulted in severe diarrhoea with no increase in height velocity or IGF-1 level.
- Commenced on treatment with 120µg/kg twice daily of rhIGF-1.
- After two years of treatment, height improved from -4.40 to -1.48 SDS and weight from -7.95 to -0.94 SDS.
- Serum IGF-1 level normalised and age-appropriate motor milestones were achieved.
- Exome sequencing results are awaited.

Conclusion

This child with IGF-1 deficiency associated with severe failure to thrive of unknown aetiology has shown excellent linear and developmental responses to within-label use of rhIGF-1 therapy and continues to benefit from this treatment.